Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Shenzhen YHLO Biotech Co., Ltd.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Shenzhen YHLO Biotech Co., Ltd.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Shenzhen YHLO Biotech Co., Ltd.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With a 2025 P/E ratio at 33.27 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.19B - -
13.19B
BBB
12.57B - - - - - - -
9.16B -
BBB
- -
5.46B
B
5.25B
AA
-
5.14B
BBB
4.8B
BB
-
4.7B -
A
- - - - -
4.43B - - - - - - -
Average 6.59B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Equities
  3. 688575 Stock
  4. Ratings Shenzhen YHLO Biotech Co., Ltd.